39 related articles for article (PubMed ID: 35389550)
1. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition.
Das N; Dahiya M; Gupta R; Rai S; Singh S; Prajapati VK; Kumar L; Sharma A; Sahoo RK; Gogia A
Cytometry B Clin Cytom; 2022 Jul; 102(4):292-302. PubMed ID: 35212134
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
3. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
[TBL] [Abstract][Full Text] [Related]
5. Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma.
Das N; Dahiya M; Gupta R; Kumar L; Sharma A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A
Cytometry B Clin Cytom; 2022 May; 102(3):209-219. PubMed ID: 35389550
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
7. Measurable disease evaluation in patients with myeloma.
Roshal M
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
9. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
[TBL] [Abstract][Full Text] [Related]
10. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
Bal S; Weaver A; Cornell RF; Costa LJ
Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]